JP2017526368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526368A5 JP2017526368A5 JP2017511675A JP2017511675A JP2017526368A5 JP 2017526368 A5 JP2017526368 A5 JP 2017526368A5 JP 2017511675 A JP2017511675 A JP 2017511675A JP 2017511675 A JP2017511675 A JP 2017511675A JP 2017526368 A5 JP2017526368 A5 JP 2017526368A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- kynureninase
- enzyme
- composition
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 33
- 102200155474 rs397507512 Human genes 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 108010031676 Kynureninase Proteins 0.000 claims description 18
- 102000005447 kynureninase Human genes 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 15
- 102200011638 rs587777189 Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 102220350170 c.295G>T Human genes 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 9
- 101001021858 Homo sapiens Kynureninase Proteins 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 241000238631 Hexapoda Species 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 241000233866 Fungi Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000001093 anti-cancer Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102220020916 rs80357276 Human genes 0.000 claims description 4
- 102220392946 rs181428774 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims description 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002262 irrigation Effects 0.000 claims description 2
- 238000003973 irrigation Methods 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000010412 perfusion Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043663P | 2014-08-29 | 2014-08-29 | |
| US62/043,663 | 2014-08-29 | ||
| US201562120418P | 2015-02-25 | 2015-02-25 | |
| US62/120,418 | 2015-02-25 | ||
| PCT/US2015/047475 WO2016033488A1 (en) | 2014-08-29 | 2015-08-28 | Administration of kynurenine depleting enzymes for tumor therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020159230A Division JP2021006046A (ja) | 2014-08-29 | 2020-09-24 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526368A JP2017526368A (ja) | 2017-09-14 |
| JP2017526368A5 true JP2017526368A5 (enExample) | 2018-10-04 |
| JP7080053B2 JP7080053B2 (ja) | 2022-06-03 |
Family
ID=55400679
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017511675A Active JP7080053B2 (ja) | 2014-08-29 | 2015-08-28 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| JP2020159230A Pending JP2021006046A (ja) | 2014-08-29 | 2020-09-24 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020159230A Pending JP2021006046A (ja) | 2014-08-29 | 2020-09-24 | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9975959B2 (enExample) |
| EP (1) | EP3186371B1 (enExample) |
| JP (2) | JP7080053B2 (enExample) |
| CA (1) | CA2959508A1 (enExample) |
| ES (1) | ES2987380T3 (enExample) |
| IL (1) | IL250833B (enExample) |
| WO (1) | WO2016033488A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3492094A1 (en) | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| US9975959B2 (en) | 2014-08-29 | 2018-05-22 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EP3402498A1 (en) * | 2016-01-11 | 2018-11-21 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| WO2017136795A1 (en) | 2016-02-04 | 2017-08-10 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with tryptophan metabolism |
| WO2017151860A1 (en) * | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| AU2017343780B2 (en) | 2016-10-13 | 2023-08-31 | Juno Therapeutics, Inc. | Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators |
| JP2020505016A (ja) | 2017-01-06 | 2020-02-20 | シンロジック オペレーティング カンパニー インコーポレイテッド | 腫瘍細胞において免疫モジュレーターおよび抗がん治療剤を産生するようにプログラムされた微生物 |
| AU2019257340B2 (en) * | 2018-04-16 | 2025-07-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
| KR20220103944A (ko) * | 2019-10-17 | 2022-07-25 | 이케나 온콜로지, 인코포레이티드 | Peg화 키뉴레니나제 효소 및 암 치료를 위한 그의 용도 |
| EP4280347B1 (en) | 2021-01-18 | 2025-05-14 | IBIDEN Co., Ltd. | Heat transfer suppression sheet for battery pack, and battery pack |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA154754A (en) | 1912-06-19 | 1914-03-31 | Henry Blanford | Can filling and sealing machine |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US5329028A (en) | 1992-08-05 | 1994-07-12 | Genentech, Inc. | Carbohydrate-directed cross-linking reagents |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| CN1330774C (zh) | 2002-03-01 | 2007-08-08 | 国家人类基因组南方研究中心 | 犬尿氨酸水解酶多态性及其用途 |
| WO2004093871A1 (en) | 2003-03-27 | 2004-11-04 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer |
| US20070207158A1 (en) | 2003-06-17 | 2007-09-06 | Harrison Roger G | Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| JP2008237022A (ja) * | 2005-06-30 | 2008-10-09 | Osaka Prefecture | 非小細胞肺がんの予防・治療剤および診断薬 |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US8465743B2 (en) | 2009-10-01 | 2013-06-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20120085209A (ko) | 2011-01-21 | 2012-07-31 | 인제대학교 산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| WO2012099441A2 (ko) | 2011-01-21 | 2012-07-26 | 인제대학교산학협력단 | 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물 |
| RU2640913C2 (ru) | 2011-09-07 | 2018-01-12 | Дойчес Кребсфоршунгсцентрум | Средства и способы лечения и/или предотвращения рака, зависимого от природного лиганда ahr |
| BR112014008849A2 (pt) | 2011-10-20 | 2017-09-12 | Us Health | receptores quiméricos de antígeno anti-cd22 |
| EP3492094A1 (en) * | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| CN108667853B (zh) * | 2013-11-22 | 2021-06-01 | 华为技术有限公司 | 恶意攻击的检测方法和装置 |
| US9975959B2 (en) | 2014-08-29 | 2018-05-22 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| AU2019257340B2 (en) * | 2018-04-16 | 2025-07-24 | Board Of Regents, The University Of Texas System | Human kynureninase enzymes and uses thereof |
-
2015
- 2015-08-28 US US14/839,293 patent/US9975959B2/en active Active
- 2015-08-28 CA CA2959508A patent/CA2959508A1/en active Pending
- 2015-08-28 EP EP15834988.6A patent/EP3186371B1/en active Active
- 2015-08-28 WO PCT/US2015/047475 patent/WO2016033488A1/en not_active Ceased
- 2015-08-28 IL IL250833A patent/IL250833B/en unknown
- 2015-08-28 ES ES15834988T patent/ES2987380T3/es active Active
- 2015-08-28 JP JP2017511675A patent/JP7080053B2/ja active Active
-
2018
- 2018-04-25 US US15/961,968 patent/US11168142B2/en active Active
-
2020
- 2020-09-24 JP JP2020159230A patent/JP2021006046A/ja active Pending
-
2021
- 2021-10-11 US US17/498,520 patent/US20220275099A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526368A5 (enExample) | ||
| JP6894086B2 (ja) | 新規抗ｃｃｒ８抗体 | |
| ES2759248T3 (es) | Constructos de anticuerpo para CDH19 y CD3 | |
| CN108473572B (zh) | 用于治疗血源性癌症的免疫检查点抑制剂 | |
| ES2818229T3 (es) | Formulación anti-IFNAR1 estable | |
| US10005841B2 (en) | Method of treating a solid tumor with IL1RAP antibodies | |
| ES2986360T3 (es) | Proteínas de unión a antígeno que se unen a PD-L1 | |
| ES2882157T3 (es) | Productos terapéuticos de anticuerpos que se unen a CTLA4 | |
| JP2016533753A5 (enExample) | ||
| UA124254C2 (uk) | Біспецифічна антигензв'язувальна молекула, яка активує t-клітини | |
| US12252746B2 (en) | Anti-CD46 antibodies and methods of use | |
| UA114883C2 (uk) | Антитіло до рецептора епідермального фактора росту-3 (her3) | |
| ES2930681T3 (es) | Linfocitos T transfectados y receptores de linfocito T para el uso en la inmunoterapia contra el cáncer | |
| KR20150036700A (ko) | Cd22에 대해 특이적인 항체 및 이들의 사용 방법 | |
| WO2016112855A1 (zh) | 抗cd19单克隆抗体及其制备方法 | |
| WO2008135237A1 (en) | Complement factor h-derived short consensus repeat-antibody constructs | |
| CN109748968A (zh) | Bcma特异性嵌合抗原受体t细胞及其应用 | |
| US12161720B2 (en) | Cell assembly-mediated delivery of checkpoint inhibitors for cancer immunotherapy | |
| CN114716541A (zh) | 抗冠状病毒的全人广谱中和抗体76e1及其应用 | |
| KR20230084478A (ko) | 면역원성 코로나 바이러스 융합 단백질 및 관련 방법 | |
| CN113194925A (zh) | 抗体制剂 | |
| UA129953C2 (uk) | АНТИТІЛО ПРОТИ Sema3A ТА ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ ОЧЕЙ | |
| CN108794624A (zh) | 抗h7n9流感病毒的中和性单克隆抗体 | |
| CN111423507B (zh) | 广谱性中和流感病毒的全人抗体 | |
| WO2018094322A1 (en) | Novel fungal toxins and methods related to the same |